Seth Klarman
Baupost Group
Seth Klarman IDENIX PHARMACEUTICALS LLC stake
total: 269
Baupost Group IDIX trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 3
- Held since:
- 2013 Q2 or earlier
- Held for:
- 5+ quarters
- Latest activity:
- 2014 Q3
According to 2026 Q1 report, Seth Klarman doesn't hold any IDENIX PHARMACEUTICALS LLC (IDIX) shares. Baupost Group has held IDIX since at least 2013 Q2 with about 26.77M shares in our earliest available record. Since at least 2013 Q2, Baupost Group has made 4 more transactions.
When did Seth Klarman sell IDENIX PHARMACEUTICALS LLC (IDIX)?
Seth Klarman sold off the entire IDENIX PHARMACEUTICALS LLC (IDIX) position in 2014 Q3.
Estimated cost basis*
- Weighted AVG buy price:
- $4.66
- Weighted AVG sell price:
- $23.80
Seth Klarman's historical trades in IDENIX PHARMACEUTICALS LLC
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2014 Q3
|
0.00%
|
$23.81
|
-100% (-53,331,109)
|
|||
|
2014 Q1
|
7.32%
|
$5.68
|
+44.49% (+16,420,241)
|
|||
|
2013 Q4
|
6.25%
|
$5.98
|
+24.42% (+7,245,175)
|
|||
|
2013 Q3
|
4.40%
|
$5.19
|
+10.83% (+2,898,693)
|
|||
|
2013 Q2
|
2.40%
|
$3.61
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.